Qingqing Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qingqing Zhou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Hongmei Yang
1 shared publicationJian Lin
1 shared publicationJichao Qin
1 shared publicationJinling Jiang
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationJun Ji
Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication- Jun Zhang
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by Elsevier in SSRN Electronic Journal
Programmable Nucleic Acid Nanospheres Coordinate Lactate Modulation and cGAS-STING Signaling Activation to Enhance Antitumor Immunity
Activation of the cGAS-STING pathway represents a strategy for cancer immunotherapy. However, the efficacy of STING agonists is not only hindered by delivery barriers (poor stability and targeting), but also by tumor-intrinsic signaling dysfunctions, notably STING depletion and lactate-driven cGAS-STING pathway inhibition. Here, we develop a tumor-targeted programmable DNA nanosphere (DNS-STING-STP) that potentiates colorectal cancer immunotherapy through the restoration of STING signaling and alleviation of lactate-associated immunosuppression. DNS-STING-STP is generated via one-pot manganese-mediated rolling circle amplification, integrating interferon-stimulatory DNA motifs (ISD-dsDNA), a STING protein lacking the transmembrane (TM) domain (STINGΔTM), stiripentol, and the nucleolin-targeting AS1411 aptamer into a nanoplatform. Following nucleolin-mediated uptake, the nanoassembly exploits manganese-facilitated lysosomal escape to release its cargoes into the cytosol. Stiripentol alleviates lactate-mediated suppression of cGAS activity, while ISD-dsDNA, manganese ions, and STINGΔTM synergistically augment cGAS-STING pathway. DNS-STING-STP triggered dendritic cell maturation and cytokine secretion in vitro. In vivo, it reprogrammed the immunosuppressive tumor microenvironment by expanding effector cells (DCs, CD8+ T, NK cells) and depleting suppressive myeloid cells. Furthermore, DNS-STING-STP synergized with anti-PD-L1 blockade, resulting in colorectal tumor suppression and extended survival. Thus, this work establishes a strategy that couples targeted agonism with the correction of tumor-intrinsic cGAS-STING pathway dysfunction to amplify antitumor immunity.
- 3 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProgrammable Nucleic Acid Nanospheres Coordinate Lactate Modulation and cGAS-STING Signaling Activation to Enhance Antitumor Immunity
Activation of the cGAS-STING pathway represents a strategy for cancer immunotherapy. However, the efficacy of STING agonists is not only hindered by delivery barriers (poor stability and targeting), but also by tumor-intrinsic signaling dysfunctions, notably STING depletion and lactate-driven cGAS-STING pathway inhibition. Here, we develop a tumor-targeted programmable DNA nanosphere (DNS-STING-STP) that potentiates colorectal cancer immunotherapy through the restoration of STING signaling and alleviation of lactate-associated immunosuppression. DNS-STING-STP is generated via one-pot manganese-mediated rolling circle amplification, integrating interferon-stimulatory DNA motifs (ISD-dsDNA), a STING protein lacking the transmembrane (TM) domain (STINGΔTM), stiripentol, and the nucleolin-targeting AS1411 aptamer into a nanoplatform. Following nucleolin-mediated uptake, the nanoassembly exploits manganese-facilitated lysosomal escape to release its cargoes into the cytosol. Stiripentol alleviates lactate-mediated suppression of cGAS activity, while ISD-dsDNA, manganese ions, and STINGΔTM synergistically augment cGAS-STING pathway. DNS-STING-STP triggered dendritic cell maturation and cytokine secretion in vitro. In vivo, it reprogrammed the immunosuppressive tumor microenvironment by expanding effector cells (DCs, CD8+ T, NK cells) and depleting suppressive myeloid cells. Furthermore, DNS-STING-STP synergized with anti-PD-L1 blockade, resulting in colorectal tumor suppression and extended survival. Thus, this work establishes a strategy that couples targeted agonism with the correction of tumor-intrinsic cGAS-STING pathway dysfunction to amplify antitumor immunity.
- Open Access
- 9 June 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (6) , 1-14
HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer
B cell receptor associated protein 31 (BAP31) is closely associated with tumor progression, while the role and mechanism of BAP31 in gastric cancer (GC) remains unknown. This study explored that BAP31 was upregulated in GC tissues and high expression indicated poor survival of GC patients. BAP31 knockdown inhibited cell growth and induced G1/S arrest. Moreover, BAP31 attenuation increased the lipid peroxidation level of the membrane and facilitated cellular ferroptosis. Mechanistically, BAP31 regulated cell proliferation and ferroptosis by directly binding to VDAC1 and affected VDAC1 oligomerization and polyubiquitination. HNF4A was bound to BAP31 at the promoter and increased its transcription. Furthermore, knockdown of BAP31 inclined to make GC cells vulnerable to 5-FU and ferroptosis inducer, erastin, in vivo and in vitro. Our work suggests that BAP31 may serve as prognostic factor for gastric cancer and act as potential therapeutic strategy for gastric cancer.
- 9 June 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (6) , 1-14
Open AccessHNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer
B cell receptor associated protein 31 (BAP31) is closely associated with tumor progression, while the role and mechanism of BAP31 in gastric cancer (GC) remains unknown. This study explored that BAP31 was upregulated in GC tissues and high expression indicated poor survival of GC patients. BAP31 knockdown inhibited cell growth and induced G1/S arrest. Moreover, BAP31 attenuation increased the lipid peroxidation level of the membrane and facilitated cellular ferroptosis. Mechanistically, BAP31 regulated cell proliferation and ferroptosis by directly binding to VDAC1 and affected VDAC1 oligomerization and polyubiquitination. HNF4A was bound to BAP31 at the promoter and increased its transcription. Furthermore, knockdown of BAP31 inclined to make GC cells vulnerable to 5-FU and ferroptosis inducer, erastin, in vivo and in vitro. Our work suggests that BAP31 may serve as prognostic factor for gastric cancer and act as potential therapeutic strategy for gastric cancer.